Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxford BioMedica has initiated work on a second Chimeric Antigen Receptor T cell (CART) programme for an undisclosed indication.
Subscribe to our email newsletter
Under an agreement signed with Novartis in October 2014, Oxford BioMedica will undertake process development and manufacturing for the lentiviral vector associated with the new programme.
Oxford BioMedica is currently manufacturing lentiviral vector expressing CTL019 for Novartis and carrying out process development work to establish the next-generation manufacturing process.
The Group also granted Novartis a non-exclusive licence in oncology under the Group’s LentiVector platform and an exclusive licence for the worldwide development and commercialisation of all CART cell products arising from the process development collaboration.
In return, Oxford BioMedica will receive undisclosed royalties on potential future sales of CART products covered by the agreement.
Commenting on the announcement, Oxford BioMedica John Dawson said: "We are excited to be providing Novartis with the licence, process development and manufacturing that they require for CTL019 and now for a second CART programme.
"Oxford BioMedica is recognised as a world leader in the field of lentiviral vectors and we are delighted to be supporting clinical programmes where the need for this type of medical intervention is vital."